Wockhardt Limited announced that two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food&Drug Administration (FDA).
QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by the Centers for Disease Control. QIDP status allows for fast track review of the drug application by U.S. FDA, paving way for an early launch. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.
Dr. Habil Khorakiwala, Wockhardt Founder & Chairman said, "Globally there is a significant antibiotic vacuum due to dual impact of rise in new resistant pathogens and declining research in this area which causes over 50,000 deaths in USA and Europe combined despite having excellent healthcare services.
"The emerging world may as well be sitting on an antibiotic time-bomb ready to explode. Superficially the bacterial diseases can be divided in two categories, gram positive and gram negative and these pathogens have prevalence in both of them. Over the years Wockhardt has developed a strong anti-infective program which focuses on development of drugs which target this antibiotic gap in both gram positive and gram negative domains. These two drugs act against one of the globally rising class of pathogens MRSA (Methicillin-resistant Staphylococcus Aureus) which causes a range of diseases from the skin infection to severe respiratory infections.
"In case of severe infections like Hospital Acquired Pneumonia (HAP) current medical cure has a very limited reach causing a high unmet need and mortality. Both of these drugs are effective against MRSA and have shown potential in treatment of HAP. WCK 771 is an intravenous (IV) drug while WCK 2349 is a solid oral tablet, which is a significant positive for the drug development scenario as currently there is very little advance drug research in developing solid oral dosages. Most of the research is in developing intravenous drugs which requires significantly higher medical attention and increased rate of hospitalization wherein the chances of catching other infections is very high.
"In addition to the fast track review of its drug application, QIDP status also grants a 5 year extension to the drug patents in USA which is a major support for the commercial aspect of the drug. These drugs will be entering in their global Phase -3 clinical trials early next year."
Wockhardt started its Anti-infective program 17 years back in 1997 to focus on developing next generation antibiotics.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- The Number Of My Publications Has Four Digits
- Matter Can Potentially Accelerate The Expansion Of The Universe
- Professor Frenkel: Why Shouldn't We Drop Algebra From Our Education System?
- The Geology Of Wine
- Machines Can Learn To Respond To New Situations Like Human Beings Would
- New Gene Testing Technology Finds Cancer Risks 'hiding In Plain Sight'
- Why Does Anyone Still Believe In The Loch Ness Monster?
- "I have a fair amount of math and physics background, and I am sorry but this is not excellent...."
- "There are even papers considering possible dark energy fields that would couple to the standard..."
- "Dear Hank, the United Nations are just a silly NGO. They are not running my country and they are..."
- "He wasn't kicked out of academia, so you owe him an apology in that sense. With his sensational..."
- "Why not to spare us details, which are commonly known? http://mathforum.org/kb/thread.jspa?messageID=54971..."
- Exposure to particulate air pollutants associated with numerous types of cancer
- Exposure to particulate air pollutants associated with numerous cancers
- Don't retweet if you want to remember
- Theoretical tiger chases statistical sheep to probe immune system behavior
- Metal hip replacements implanted since 2006 more prone to failure